159 related articles for article (PubMed ID: 12918769)
1. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results.
Davatchi F; Shahram F; Chams H; Jamshidi AR; Nadji A; Chams C; Akbarian M; Gharibdoost F
Adv Exp Med Biol; 2003; 528():579-84. PubMed ID: 12918769
[No Abstract] [Full Text] [Related]
2. Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behçet's disease. A preliminary report.
Shahram F; Davatchi F; Chams H; Nadji A; Jamshidi A; Akbarian M; Gharibdoost F
Adv Exp Med Biol; 2003; 528():571-3. PubMed ID: 12918767
[No Abstract] [Full Text] [Related]
3. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.
Davatchi F; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Sadeghi Abdollahi B; Faezi T; Akhlaghi M; Ashofteh F
Int J Rheum Dis; 2013 Oct; 16(5):568-77. PubMed ID: 24164845
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).
Davatchi F; Shams H; Rezaipoor M; Sadeghi-Abdollahi B; Shahram F; Nadji A; Chams-Davatchi C; Akhlaghi M; Faezi T; Naderi N
Int J Rheum Dis; 2010 Aug; 13(3):246-52. PubMed ID: 20704622
[TBL] [Abstract][Full Text] [Related]
5. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.
Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N
Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325
[TBL] [Abstract][Full Text] [Related]
6. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
Kötter I; Zierhut M; Eckstein A; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Kanz L; Stübiger N
Adv Exp Med Biol; 2003; 528():521-3. PubMed ID: 12918755
[No Abstract] [Full Text] [Related]
7. Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Behçet's disease.
Ermakova NA
Adv Exp Med Biol; 2003; 528():563-5. PubMed ID: 12918765
[No Abstract] [Full Text] [Related]
8. Behçet's disease: visual acuity after 5 years in patients with alpha-interferon treatment.
Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
Adv Exp Med Biol; 2003; 528():525-8. PubMed ID: 12918756
[No Abstract] [Full Text] [Related]
9. Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a.
Stübiger N; Besch D; Deuter CM; Zierhut M; Kötter I
Adv Exp Med Biol; 2003; 528():529-32. PubMed ID: 12918757
[No Abstract] [Full Text] [Related]
10. Ocular Manifestations and Visual Outcomes of Behçet's Uveitis in a Thai population.
Pathanapitoon K; Kunavisarut P; Saravuttikul FA; Rothova A
Ocul Immunol Inflamm; 2019; 27(1):2-6. PubMed ID: 29020486
[TBL] [Abstract][Full Text] [Related]
11. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study.
Mohammadi M; Shahram F; Shams H; Akhlaghi M; Ashofteh F; Davatchi F
Int J Rheum Dis; 2017 Sep; 20(9):1269-1276. PubMed ID: 28524639
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease.
Bae JH; Lee SC
Retina; 2012 Jul; 32(7):1395-402. PubMed ID: 22012204
[TBL] [Abstract][Full Text] [Related]
14. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
[TBL] [Abstract][Full Text] [Related]
16. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
17. Ocular involvement in Behçet's disease.
Peplinski LS
J Am Optom Assoc; 1989 Nov; 60(11):854-7. PubMed ID: 2607080
[TBL] [Abstract][Full Text] [Related]
18. Gender influence on ocular manifestations and their outcome in Behcet's Disease. A long-term follow-up of up to 20 years.
Davatchi F; Shahram F; Shams H; Nadji A; Chams-Davatchi C; Akhlaghi M; Faezi ST; Ashofteh F; Sadeghi-Abdollahi B
Clin Rheumatol; 2011 Apr; 30(4):541-7. PubMed ID: 20857156
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of the ocular form of Behçet disease with cyclosporin A].
Pahlitzsch T; Wyrobisch W; Kämpe C; Wiederholt M
Klin Monbl Augenheilkd; 1990 Jun; 196(6):466-9. PubMed ID: 2376943
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis: report of three patients.
Davatchi F; Nikbin B; Shams H; Sadeghi Abdollahi B; Mohyeddin M; Shahram F
Int J Rheum Dis; 2013 Apr; 16(2):139-47. PubMed ID: 23773637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
